Dal, Mehmet SinanKarakus, AbdullahCakar, Merih KizilUlu, Bahar UncuHattapoglu, ElifEkmen, Mehmet OnderUlas, Turgay2024-04-242024-04-2420161940-5901https://hdl.handle.net/11468/20721Background: Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder characterized by immune-mediated platelet destruction and reduced platelet production. As the pathophysiology of the disease got clear, thrombopoietin receptor (TPO-R) agonists have been preferred in recent years, which seems to be an effective option in the treatment of resistant cases. Eltrombopag, a TPO-R agonist, is a second or third line medical treatment option for adults with chronic ITP. Objective: To determine the efficacy and safety of long-term eltrombopag treatment in treatment-refractory patients with primary ITP was the aim of this study. Materials and Methods: Retrospective data of 34 patients with refractory ITP who were treated with eltrombopag were examined. Efficacy and safety of the eltrombopag treatment was evaluated. Results: The total rate of response was 82%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 14 (interquartile range: 7-28) days. In two patients, thrombosis was observed with no other additional risk factors due to or related to thrombosis. Conclusion: In spite of the fact that the responses to eltrombopag were satisfactory, patients need to be monitored closely for increasing platelet counts as well as thromboembolic events.eninfo:eu-repo/semantics/closedAccessImmune ThrombocytopeniaThrombopoietin Receptor AgonistThrombosisEltrombopagArticle991870718711WOS:0003866711002052-s2.0-84989171909N/AQ4